Cargando…

Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA

OnabotulinumtoxinA is one of the main preventive treatments for chronic migraine. Despite that up to one third of patients with chronic migraine suffer from daily headache, these individuals have hardly been studied. We conducted a prospective cohort study, including patients with chronic migraine a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-Pías, Enrique, Guerrero, Ángel L., Sierra, Álvaro, Trigo, Javier, García-Azorín, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234385/ https://www.ncbi.nlm.nih.gov/pubmed/34205832 http://dx.doi.org/10.3390/toxins13060432

Ejemplares similares

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
por: Ferrari, Michel D., et al.
Publicado: (2022)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown
por: Gonzalez-Martinez, Alicia, et al.
Publicado: (2021)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
por: Young, William B., et al.
Publicado: (2019)

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
por: Winner, Paul K., et al.
Publicado: (2020)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

OnabotulinumtoxinA in the treatment of refractory chronic cluster headache
por: Lampl, Christian, et al.
Publicado: (2018)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

Clinical characteristics of nummular headache and differentiation between spontaneous and posttraumatic variant: an observational study
por: Trigo, Javier, et al.
Publicado: (2019)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Rothrock, John F., et al.
Publicado: (2019)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity
por: Onan, Dilara, et al.
Publicado: (2022)

OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
por: Pedraza, María Isabel, et al.
Publicado: (2015)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
por: Byun, Jung-Ick, et al.
Publicado: (2017)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2020)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
por: Szok, Délia, et al.
Publicado: (2015)

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
por: Chiang, Chia-Chun, et al.
Publicado: (2017)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
por: Sastre Real, María, et al.
Publicado: (2020)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

Correction to: OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2021)

Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review
por: Shaterian, Negar, et al.
Publicado: (2022)

OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
por: Ray, Jason C., et al.
Publicado: (2021)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study
por: Stark, Catherine, et al.
Publicado: (2019)

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
por: Silberstein, Stephen D, et al.
Publicado: (2015)

Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
por: Robertson, Carrie E, et al.
Publicado: (2012)

Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
por: Oterino, A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jr2rk97c0sl02u8raf6c5g8rqs